The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...
A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and ...
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback